New research has demonstrated that total IV anesthesia (TIVA) with remimazolam plus remifentanil has a superior hemodynamic profile to that of propofol and remifentanil in ASA physical status III/IV patients undergoing noncardiac surgery.
This phase 3 multicenter European trial (CNS7056-022) concluded that use of remimazolam for TIVA reduced critical hypotensive events and mean arterial pressure (MAP) decreases less than 65 mm Hg in this patient population.
“As we know, intraoperative